Press Releases Asarina Pharma AB

Equities

ASAP

SE0011641794

Market Closed - Nasdaq Stockholm Other stock markets 11:11:04 2024-05-02 am EDT			5-day change	1st Jan Change
0.926 ^SEK	-4.34%		-1.07%	+5.23%

Feb. 27	Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	Feb. 27	AQ
Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	Nov. 30	AQ
Asarina Pharma updates on partnering and financials	Nov. 16	AQ
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	23-08-23	AQ
ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	23-05-24	AQ
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	23-05-22	AQ
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	23-05-08	AQ
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	23-05-05	AQ
Asarina Pharma AB (publ) releases Annual Report 2022	23-05-01	AQ
Asarina Pharma AB (publ) releases Annual Report 2022	23-04-28	AQ
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	23-04-18	AQ
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	23-04-03	AQ
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	23-04-01	AQ
Asarina Pharma AB (publ) releases Year-End Report 2022	23-02-27	AQ
Last Patient Last Visit for landmark Tourette Syndrome study	23-02-02	AQ
Asarina Pharma - Patient recruitment completed in landmark Tourette syndrome study	22-10-17	AQ
Patient recruitment completed in landmark Tourette syndrome study	22-10-14	AQ
Extensive new preclinical study significantly increases the Translatability of Asarina Pharma's findings on key stress mechanism implicated in Tourette Syndrome and OCD	22-10-06	AQ
Asarina Pharma AB (publ) Q2 2022 Report released	22-08-25	AQ
Asarina Pharma carries out a directed share issue following a request for loan conversion from Ostersjostiftelsen	22-06-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Asarina Pharma AB

Equities

ASAP

SE0011641794

Press Releases

Filters